Markers of small cell lung cancer

Lung cancer is the number one cause of cancer death; however, no specific serum biomarker is available till date for detection of early lung cancer. Despite good initial response to chemotherapy, small-cell lung cancer (SCLC) has a poor prognosis. Therefore, it is important to identify molecular markers that might influence survival and may serve as potential therapeutic targets. The review aims to summarize the current knowledge of serum biomarkers in SCLC to improve diagnostic efficiency in the detection of tumor progression in lung cancer. The current knowledge on the known serum cytokines and tumor biomarkers of SCLC is emphasized. Recent findings in the search for novel diagnostic and therapeutic molecular markers using the emerging genomic technology for detecting lung cancer are also described. It is believed that implementing these new research techniques will facilitate and improve early detection, prognostication and better treatment of SCLC.

[1]  M. Gaub,et al.  Plasma DNA microsatellite panel as sensitive and tumor‐specific marker in lung cancer patients , 2003, International journal of cancer.

[2]  S. Honsawek,et al.  The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  J. Nikliński,et al.  Evaluation of carcinoembryonic antigen (CEA) and brain-type creatine kinase (CK-BB) in serum from patients with carcinoma of the lung. , 1991, Neoplasma.

[4]  N. Maki,et al.  Enzyme‐linked Immunosorbent Assay of Pro‐gastrin‐releasing Peptide for Small Cell Lung Cancer Patients in Comparison with Neuron‐specific Enolase Measurement , 1995, Japanese journal of cancer research : Gann.

[5]  L Ceriani,et al.  Immunoradiometric Assay of Chromogranin a in the Diagnosis of Small Cell Lung Cancer: Comparative Evaluation with Neuron-Specific Enolase , 2001, The International journal of biological markers.

[6]  R. Salgia,et al.  Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 , 2000, Oncogene.

[7]  K. Aoyagi,et al.  Enzyme immunoassay of immunoreactive progastrin-releasing peptide(31-98) as tumor marker for small-cell lung carcinoma: development and evaluation. , 1995, Clinical chemistry.

[8]  R. Stahel,et al.  Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation , 2003, Cell Death and Differentiation.

[9]  Christopher Haslett,et al.  Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo , 1999, Nature Medicine.

[10]  R. Simon,et al.  Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Y. Eto,et al.  Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer , 2002, Journal of Cancer Research and Clinical Oncology.

[12]  P. Lamy,et al.  Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. , 2003, Lung cancer.

[13]  Y. Shimosato,et al.  Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.

[14]  M. Provencio,et al.  Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  B. Westerman,et al.  Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  P. Carlson,et al.  c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. , 1993, Cancer research.

[17]  M. von Knebel Doeberitz,et al.  Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP‐specific RT‐PCR , 2001, International journal of cancer.

[18]  A. Kurt,et al.  Microsatellite alterations in plasma DNA of small cell lung cancer patients , 1996, Nature Medicine.

[19]  K. Yamaguchi,et al.  Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. , 1994, Cancer research.

[20]  R. Weller,et al.  International Histological Classification of Tumours , 1981 .

[21]  E. Brambilla,et al.  Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma , 2003, The Journal of pathology.

[22]  John D Minna,et al.  Differential Inactivation of Caspase-8 in Lung Cancers , 2002, Cancer biology & therapy.

[23]  E. Spindel,et al.  Gastrin-releasing peptide gene expression in small cell and large cell undifferentiated lung carcinomas. , 1991, Human pathology.

[24]  C. Becker,et al.  Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor α1 subunit in small-cell lung cancer cells , 2003, Oncogene.

[25]  T. Nakamura,et al.  Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. , 1993, British Journal of Cancer.

[26]  J. Winter,et al.  A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells , 2003, Cancer Immunology, Immunotherapy.

[27]  Y. Nishiwaki,et al.  Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. , 2003, Lung cancer.

[28]  T Takahashi,et al.  Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. , 1991, Oncogene.

[29]  A. Gazdar,et al.  Telomerase activity in small-cell and non-small-cell lung cancers. , 1995, Journal of the National Cancer Institute.